Product Description
Cigna Qingdao is mainly engaged in the intermediates of febuxostatin, ceflothrin, eprazole, flubiprofen, phenalidone, tovaptan, rivaroxaban and Avanafil, terbinafine intermediates, thioacetamide and thiophene and their derivatives.
AI Product Description
*The following content is generated by AI and is for reference only.
4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine is a specialized heterocyclic intermediate widely utilized in medicinal chemistry and organic synthesis research. This compound features a complex pyrrolo[2,3-d]pyrimidine core scaffold, which serves as a privileged structure in the development of kinase inhibitors and other bioactive agents. The molecule incorporates a 1H-pyrazole moiety at the C4 position and a protected hydroxymethyl group at the C7 position, specifically utilizing a 2-(trimethylsilyl)ethoxymethyl (SEM) protecting group. This SEM group is strategically employed to protect reactive amine or alcohol functionalities during multi-step synthetic sequences, offering stability under various reaction conditions while remaining easily removable when required for final product assembly.
The precise Chemical Abstracts Service (CAS) number associated with this specific derivative is 1016958-58-9. Its molecular formula is C14H22N6OSi, reflecting a molecular weight of approximately 322.43 g/mol. The presence of the trimethylsilyl group not only provides steric bulk but also enhances solubility in organic solvents, facilitating purification processes such as column chromatography. Researchers primarily utilize this reagent as a critical building block for constructing advanced nucleoside analogs and purine-mimetic compounds. These analogs are often investigated for their potential therapeutic applications in treating viral infections, cancer, and inflammatory diseases due to their ability to modulate enzyme activity or interfere with nucleic acid metabolism.
In laboratory settings, this compound acts as a precursor for the synthesis of more complex pharmacophores. The selective protection offered by the SEM group allows chemists to perform regioselective modifications on the pyrazole ring or the pyrimidine core without affecting the sensitive positions. Consequently, it plays an indispensable role in high-throughput screening campaigns and structure-activity relationship (SAR) studies. While not typically marketed as a finished pharmaceutical drug itself, its value lies in its utility within the discovery phase of drug development. Availability from chemical suppliers ensures that researchers can access high-purity material necessary for rigorous experimental validation. As a versatile synthetic tool, 4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine continues to support advancements in heterocyclic chemistry and the design of next-generation therapeutic candidates.